Who is sponsoring NCT01493427?

NCT01493427 is sponsored by Alcon Research.

What condition does NCT01493427 study?

NCT01493427 studies Open-Angle Glaucoma, Ocular Hypertension.

What drugs are being tested in NCT01493427?

Interventions: Travoprost 0.004%.

What is the status of NCT01493427?

NCT01493427 is currently COMPLETED.

Last reviewed 2014-05-09 · How we verify

Multi-Center Study Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (0.004% Travoprost) in Patients Previously on Latanoprost 0.005% or Bimatoprost 0.01% Ophthalmic Solution Monotherapy

NCT01493427 Phase 4 COMPLETED Results posted

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

Details

Lead sponsor	Alcon Research
Phase	Phase 4
Status	COMPLETED
Enrolment	202
Start date	2011-12
Completion	2013-02

Conditions

Open-Angle Glaucoma
Ocular Hypertension

Interventions

Travoprost 0.004%

Primary outcomes

Mean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline) — Baseline, Week 12
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.